Clinical Trials Logo

Leukemia, Lymphoid clinical trials

View clinical trials related to Leukemia, Lymphoid.

Filter by:

NCT ID: NCT04578613 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Start date: January 8, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

NCT ID: NCT04560322 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Start date: October 19, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: - obinutuzumab - venetoclax - acalabrutinib

NCT ID: NCT04556084 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Blinatumomab Bridging Therapy

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

The investigator is testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to HCT to improve post-HCT outcomes.

NCT ID: NCT04546906 Recruiting - B-ALL Clinical Trials

Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD22 CAR-T cell in the treatment of recurrent or refractory B-ALL

NCT ID: NCT04544592 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

Start date: February 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.

NCT ID: NCT04534634 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia(R/R-ALL)

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of IFN-α combined with CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).

NCT ID: NCT04532281 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.

NCT ID: NCT04532268 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Start date: August 23, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma.

NCT ID: NCT04532203 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

NCT ID: NCT04530565 Recruiting - Clinical trials for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Start date: January 25, 2021
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.